Over time MNTA's cash build will start to overwhelm and investors will take notice. Not sure how many quarters it will take. The only sure TEVA killer will be generic Copaxone approval. As Craig Wheeler stated regarding characterizing Copaxone- hits MNTA's sweet spot! I like Wheelers description of MNTA now being the racecar that had been stuck on idle and is now ready to accelerate. Still waiting for the shares to appreciate!!
Market Data 
Markets 
AI
